The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
0304 GMT - Celltrion's growth this year could be driven by newer biosimilars rather than legacy products, Nomura analysts say in a note. The South Korean pharmaceutical company guides for 20%-25% revenue growth and a mid-30% operating margin in 2026, the analysts led by Cindy Park note. Celltrion's newer biosimilars--Zymfentra, Yuflyma, Vegzelma and Steqeyma--could support the guidance, whilelegacy products including Remsima, Truxima and Herzuma provide steady revenue, they say. Those "young portfolio" products could lift their share above the current 50%, likely positioning the company for a new earnings cycle beyond its legacy flagship products, they add. (kwanwoo.jun@wsj.com)
1102 GMT - Sanofi and Regeneron might face competition in the market for eczema treatments after Pfizer reported data for an experimental medicine that showed potential to be the first meaningful rival to their Dupixent blockbuster drug, Citi analysts say in a research note. In a midstage trial, Pfizer's tilrekimig achieve efficacy for eczema--also known as atopic dermatitis--with potential to be competitive against Dupixent and placebo-like safety, Citi says. Results from a late-stage study could come between 2027 and 2028 and approval a year later, suggesting tilrekimig could hurt Dupixent sales in the final years before its patents expire, the analysts say. Sanofi shares fall 0.3%. Regeneron and Pfizer are down 1.2% and 0.3%, respectively, in U.S. premarket trading. (adria.calatayud@wsj.com)
1056 GMT - Roche Holding's recent pipeline updates show mixed fortunes across its immunology and oncology businesses, analysts at Berenberg say. The Swiss pharmaceutical company recently presented promising data for its Gazyva drug in lupus, which suggests a growing opportunity in immune-mediated diseases, the analysts say. Berenberg raises its estimate on Gazyva peak sales to 3.7 billion Swiss francs from 2.1 billion francs. Nevertheless, negative results for breast cancer drug candidate giredestrant as a first-line treatment mean the majority of its opportunity is in the so-called adjuvant setting, when drugs are given after tumor-removal surgery, the analysts add. Berenberg cuts its estimate for giredestrant peak sales to 8 billion francs from 11 billion francs. Shares fall 1.3%. (adria.calatayud@wsj.com)
0827 GMT - European stocks fall back into the red at the opening bell as industrials and defense companies lead blue-chip indexes down. After staging a strong recovery Tuesday, the industrials-heavy DAX index slides 1.2% in Germany, with Rheinmetall falling 4.3% as newly reported profits disappoint investors. Miners and real-estate stocks push London's FTSE 100 0.7% lower. In Paris, the CAC 40 slips 0.6% as luxury names that dominate the index fall. Defense group Leonardo falls 2.2% in Italy, as the FTSE MIB declines 0.8%. The Spanish IBEX 35 trades flat, as a sharp rise for index heavyweight Inditex--up 3.4% after earnings--counters early slides for banks and healthcare stocks. (josephmichael.stonor@wsj.com)
(END) Dow Jones Newswires
March 12, 2026 04:20 ET (08:20 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
Comments